Cancer Therapeutic

Linebacker

Linebacker

A multi-faceted therapeutic for metabolic, neurologic, cancer, and infectious diseases created to mirror the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker has demonstrated success against multiple disease categories including neurological, cancer, antiviral.

We are continuing our research of the Linebacker effect.

Research

  • Dana Farber Cancer Institute

    ProPhase Labs’ wholly owned subsidiary ProPhase BioPharma has entered a two-year collaboration agreement with Dana-Farber Cancer Institute for further research and development of Linebacker-1. It will also evaluate the tumoricidal effects of the flavonoid/polyphenol.

Project Details

Linebacker is being studied for its efficacy as both a mono therapy to treat cancer and a co-therapy alongside leading cancer drugs.

Patents
  • 1
    10,123,991
  • 2
    8,034,838
Partnerships

  • Two Linebacker molecules, LB-1 & LB-2, are currently licensed to Prophase Labs through Impact Biomedical with the focus of being used as both a monotherapy against cancer and a co-therapy with other major cancer drugs.